Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Prostate

• Publication date

  2009-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pros.20941PMID 19267352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

  2008cited by this paper
• A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity

  2008cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  2007cited by this paper
• Pathologic effects of testosterone deprivation

  2007cited by this paper
• Vaccination therapy in prostate cancer

  2007influential reference
• The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1

  2006cited by this paper
• Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

  2006cited by this paper
• Management of high risk metastatic prostate cancer: the case for novel therapies.

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial

  2006cited by this paper
• Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA

  2006cited by this paper
• Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy

  2006cited by this paper
• CD4+CD25high T Cells Are Enriched in the Tumor and Peripheral Blood of Prostate Cancer Patients1

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.

  2005cited by this paper
• Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA

  2005cited by this paper
• Cancer Statistics, 2004

  2004cited by this paper
• Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation.

  2004cited by this paper
• Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer.

  2004cited by this paper
• Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

  2002cited by this paper
• Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

  2002cited by this paper
• Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

  2002cited by this paper
• Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer

  2002cited by this paper
• Identification of tumour-associated t-cell epitopes for vaccine development

  2002cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.

  2000cited by this paper
• Natural history of progression after PSA elevation following radical prostatectomy.

  1999cited by this paper
• SYFPEITHI: database for MHC ligands and peptide motifs

  1999cited by this paper
• Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

  1999influential reference
• Report of immune monitoring of prostate cancer patients undergoing T‐cell therapy using dendritic cells pulsed with HLA‐A2‐specific peptides from prostate‐specific membrane antigen (PSMA)

  1998cited by this paper
• In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.

  1997cited by this paper
• Presentation of prostate tumor antigens by dendritic cells stimulates T‐cell proliferation and cytotoxicity

  1996cited by this paper
• Prostate

  1995cited by this paper
• Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

  1994cited by this paper
• Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes.

  1994cited by this paper
• Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells

  1994cited by this paper
• The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2.

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper

• JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In‐Patient Developments 2024–2025

  2025cites this paper
• Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy

  2025cites this paper
• The Role of Therapeutic Vaccines in Cancer Immunotherapy

  2025cites this paper
• Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients

  2024cites this paper
• Reverse Vaccinology and Immunoinformatics Strategy to Screen Oncogenic Proteins and Development of a Multiepitope Peptide Vaccine Targeting Protein Kinases against Oral Cancer: An in-silico Study

  2024cites this paper
• AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients

  2024cites this paper
• iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens

  2024cites this paper
• FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

  2024cites this paper
• Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines

  2024cites this paper
• Survivin (BIRC5) Peptide Vaccine in the 4T1 Murine Mammary Tumor Model: A Potential Neoadjuvant T Cell Immunotherapy for Triple Negative Breast Cancer: A Preliminary Study

  2023cites this paper
• Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T-cell immunotherapy for triple negative breast cancer

  2023cites this paper
• Adjuvant physiochemistry and advanced nanotechnology for vaccine development.

  2023cites this paper
• Peptide-based vaccine for cancer therapies

  2023cites this paper
• Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications

  2023cites this paper
• Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer

  2023cites this paper
• Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency

  2023cites this paper
• RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug

  2022cites this paper
• Title: T-cell targeted immunotherapy against the tumor associated antigen survivin (BIRC5) as a potential neoadjuvant immunotherapy for triple negative breast cancer.

  2022cites this paper
• mRNA vaccines for COVID-19 and diverse diseases

  2022cites this paper
• Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer

  2021cites this paper
• A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

  2021cites this paper
• mRNA vaccine: a potential therapeutic strategy

  2021cites this paper
• The Peptide Vaccine of the Future

  2020cites this paper
• Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

  2020cites this paper
• HNSCC: Tumour Antigens and Their Targeting by Immunotherapy

  2020cites this paper
• Functional differences between protamine preparations for the transfection of mRNA

  2020cites this paper
• Antigens in water-in-oil emulsion: a simple antigen extraction method for analysis and proof of equal antigen distribution in vaccination syringe after mixture

  2020cites this paper
• OMV Vaccines and the Role of TLR Agonists in Immune Response

  2020cites this paper
• At the bench: Engineering the next generation of cancer vaccines

  2019cites this paper
• A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer

  2019cites this paper
• Tumor Antigens

  2019cites this paper
• Novel imiquimod nanovesicles for topical vaccination.

  2019cites this paper
• Impact of curative radiotherapy on the immune status of patients with localized prostate cancer

  2018cites this paper
• Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation

  2018cites this paper
• Design and delivery strategies of alphavirus replicon-based cervical cancer vaccines

  2018cites this paper
• Personalized cancer vaccines: adjuvants are important, too

  2018cites this paper
• Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA‐Peptide Multimer Staining Assay

  2018cites this paper
• Personalized peptide vaccines and their relation to other therapies in urological cancer

  2017cites this paper
• Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

  2017cites this paper
• Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation

  2017cites this paper
• 9-Phenanthrol enhances the generation of an CD8+ T cell response following transcutaneous immunization with imiquimod in mice.

  2017cites this paper
• Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.

  2017cites this paper
• Engineering of a self-adjuvanted iTEP-delivered CTL vaccine

  2017cites this paper
• Bone Marrow Dendritic Cells Derived Microvesicles for Combinational Immunochemotherapy against Tumor

  2017cites this paper
• The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells

  2016cites this paper
• Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

  2016cites this paper
• Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination

  2016cites this paper
• Adjuvants for peptide-based cancer vaccines

  2016cites this paper
• MYCN-targeting vaccines and immunotherapeutics

  2016cites this paper
• Current status and future prospects of peptide-based cancer vaccines.

  2016cites this paper
• RNA Nanoparticles as Potential Vaccines

  2016cites this paper
• Therapeutic and Prophylactic Cancer Vaccines

  2016cites this paper
• Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice

  2016cites this paper
• Effect of multipeptide vaccination therapy on disease outcome of patients with prostate cancer and biochemical recurrence

  2016cites this paper
• Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.

  2016cites this paper
• Peptide Vaccine: Overview

  2015cites this paper
• CpG Oligonucleotides as Cancer Vaccine Adjuvants

  2015cites this paper
• Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity.

  2015cites this paper
• Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

  2015cites this paper
• Identification of glioma-associated antigens for brain tumor immunotherapy

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• Immunotherapy of Prostate Carcinoma with biodegradable PLGA Microspheres

  2015cites this paper
• Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.

  2014cites this paper
• Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands

  2014cites this paper
• Therapeutic vaccines for cancer: an overview of clinical trials

  2014cites this paper
• MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection

  2014cites this paper
• MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines

  2014cites this paper
• Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation

  2014cites this paper
• Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

  2014cites this paper
• IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.

  2014cites this paper
• Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

  2014cites this paper
• HPV-specific immunotherapy: key role for immunomodulators.

  2014cites this paper
• Personalized peptide vaccine for treatment of advanced cancer.

  2014cites this paper
• Increasing the rate of heating: A potential therapeutic approach for achieving synergistic tumour killing in combined hyperthermia and chemotherapy

  2013cites this paper
• Toll-like Receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes

  2013cites this paper
• IMA901: a peptide vaccine in renal cell carcinoma

  2013cites this paper
• Next‐generation peptide vaccines for advanced cancer

  2013cites this paper
• Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?

  2013cites this paper
• Immunotherapy of Prostate Cancer

  2013cites this paper
• The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials.

  2013cites this paper
• Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

  2013cites this paper
• Prothymosin α and a prothymosin α-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes

  2013cites this paper
• Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

  2013cites this paper
• HLA ligandome tumor antigen discovery for personalized vaccine approach

  2013cites this paper
• Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies

  2013cites this paper
• Promiscuous survivin peptide induces robust CD4+ T‐cell responses in the majority of vaccinated cancer patients

  2012cites this paper
• Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy

  2012cites this paper
• Trial watch

  2012cites this paper
• Mathematical and Computational Models in Tumor Immunology

  2012cites this paper
• DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time

  2012cites this paper
• Trial watch

  2012cites this paper
• Entwicklung therapeutischer Peptidimpfstoffe gegen Krebs

  2012cites this paper
• Tumorvakzinierung

  2012cites this paper
• Vaccine and Cancer Therapy for Genitourinary Tumors

  2012cites this paper
• Cancer Therapy Using Viral- and Bacterial Proteins, as Vectors for Vaccines or as Carriers of Cytostatics

  2012cites this paper
• Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

  2011cites this paper
• Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T

  2011cites this paper
• Prostatakarzinom

  2011cites this paper
• Murine Polyomavirus Virus-Like Particles Carrying Full-Length Human PSA Protect BALB/c Mice from Outgrowth of a PSA Expressing Tumor

  2011cites this paper
• TLR-based immune adjuvants.

  2011cites this paper